Lungs News and Research

RSS

Non communicable diseases will cost India USD237 billion during 2006-15

Health experts participating at a roundtable organised by India Health Progress(IHP) on economic and social impact of non-communicable diseases in India are of the opinion that a concerted effort is required to address the growing burden.

25 Oct 2010

Childhood allergies and asthma linked to development in the womb

A child's chances of developing allergies or wheezing is related to how he or she grew at vital stages in the womb, according to scientists from the University of Southampton.

25 Oct 2010

Gene therapy may reverse pulmonary hypertension

A Heart and Stroke Foundation researcher has discovered what could be the first truly effective breakthrough in the diagnosis and treatment of pulmonary hypertension, a devastating, life-threatening condition which results in an enlargement of the heart.

25 Oct 2010

Research Roundup: U.S. life expectancy ratings; Medicare Advantage outlook; Should advanced cancer patients have routine screening tests?

Health Affairs: What Changes In Survival Rates Tell Us About US Health Care -- Proponents of changes in the U.S. health system have often pointed to studies that find health outcomes in this country are worse than other developed nations, even though the United States "spends well over twice the median expenditure of industrialized nations on health care, and far more than any other country as a percentage of its gross domestic product." Others point to high rates of smoking, obesity and traffic fatalities.

25 Oct 2010

Experts identify efficient way to increase minority access to colorectal cancer screening

Minority patients have a significantly decreased survival from colon cancer compared to white patients, most often as a result of a late diagnosis. To help address this problem, a team of healthcare professionals at Memorial Sloan-Kettering Cancer Center has identified an efficient way to increase minority access to lifesaving colorectal cancer screening (CRCS) in communities where multiple barriers to preventive care exist.

25 Oct 2010

UC San Diego researchers receive two federal grants for biomedical informatics

Researchers at the University of California, San Diego School of Medicine, led by Lucila Ohno-Machado, MD, PhD, chief of the Division of Biomedical Informatics in the Department of Medicine, have received two federal grants totaling more than $25 million to develop new ways to gather, analyze, use and share vast, ever-increasing amounts of biomedical information.

25 Oct 2010

Taste receptors in lungs can revolutionize treatment option for asthma

Taste receptors in the lungs. Researchers at the University of Maryland School of Medicine in Baltimore have discovered that bitter taste receptors are not just located in the mouth but also in human lungs. What they learned about the role of the receptors could revolutionize the treatment of asthma and other obstructive lung diseases.

25 Oct 2010

GE Healthcare signs definitive agreement to acquire Clarient

GE Healthcare, a unit of General Electric Company and Clarient, Inc. announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the fast-growing molecular diagnostics sector.

25 Oct 2010

Shrink announces agreement to produce high content screening tool for biotech R&D subsidiary

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it has entered into an agreement to produce a high content screening tool for its biotech R&D subsidiary, Shrink Chips LLC.

25 Oct 2010

Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis

Pharmaceutical company Pharmaxis today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis.

25 Oct 2010

72% of patients misdiagnosed with pneumonia upon readmission : Study

Patients were misdiagnosed with pneumonia at an alarming rate when they were readmitted to the hospital shortly after a previous hospitalization for the same illness, according to two Henry Ford Hospital companion studies.

25 Oct 2010

Arena's NDA receives Complete Response Letter for lorcaserin

Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese

25 Oct 2010

New research shows flu virus with D222G mutation can cause pneumonia

A variant of last year's pandemic influenza linked to fatal cases carried a mutation that enabled it to infect a different subset of cells lining the airway, according to new research. The study, due to be published next week in the Journal of Virology, suggests that the mutant virus could have impaired the lungs' ability to clear out germs.

25 Oct 2010

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the 24th Annual North American Cystic Fibrosis Conference (NACFC) October 21-23, 2010 in Baltimore, Maryland.

22 Oct 2010

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).

22 Oct 2010

TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection

A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.

22 Oct 2010

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-organ HCMV disease caused by multi-resistant virus. Details will be presented at the 48th IDSA meeting on October 23, presentation number LB-38.

22 Oct 2010

NIH awards three new SBIR grants to Taiga

Taiga Biotechnologies, Inc. today announced that the company has received three new Small Business Innovation Research (SBIR) grants from the National Institutes of Health, totaling $1.7 million. This adds to the two previous grants awarded to Taiga for various applications of its proprietary technology platforms, for a total in NIH funding to date of over $2.1 million.

22 Oct 2010

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Measuring three biomarkers in a single blood sample may improve physicians' ability to identify patients at high risk of developing chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

22 Oct 2010

UHCMC improves workflow using Toshiba's suite of systems

One of the top priorities for healthcare facilities today is improving operational efficiency. To help address this issue, University Hospitals Case Medical Center (UHCMC) in Cleveland, Ohio, rated among the best hospitals in the nation, recently purchased a suite of systems from Toshiba America Medical Systems, Inc., including an Aplio MX, two Xario XGs and two Aplio XG systems.

21 Oct 2010